BMY vs CRL: fair value comparison
Bristol-Myers Squibb Company and Charles River Laboratories International, Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BMY currently sits closer to the top of our discount ranking.
| BMY | CRL | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $66.58 | $291.50 |
| 12-month range | $46.02–$65.47 | $161.25–$232.51 |
| Sector rank | #101 of 113 Healthcare | #103 of 113 Healthcare |
| Quality grade | C | C |
| Momentum grade | B | — |
| Leverage | High | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Overbought |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · CRL fair value analysis